ATE293458T1 - Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen - Google Patents

Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen

Info

Publication number
ATE293458T1
ATE293458T1 AT97938475T AT97938475T ATE293458T1 AT E293458 T1 ATE293458 T1 AT E293458T1 AT 97938475 T AT97938475 T AT 97938475T AT 97938475 T AT97938475 T AT 97938475T AT E293458 T1 ATE293458 T1 AT E293458T1
Authority
AT
Austria
Prior art keywords
treatment
neuropathic pain
preparation containing
anticonvulsive agents
nmda receptor
Prior art date
Application number
AT97938475T
Other languages
English (en)
Inventor
Frank S Caruso
Fredrick L Minn
John W Lyle
Original Assignee
Algos Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algos Pharm Corp filed Critical Algos Pharm Corp
Application granted granted Critical
Publication of ATE293458T1 publication Critical patent/ATE293458T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97938475T 1996-08-23 1997-08-21 Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen ATE293458T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2450896P 1996-08-23 1996-08-23
PCT/US1997/014680 WO1998007447A1 (en) 1996-08-23 1997-08-21 Anticonvulsant containing composition for treating neuropathic pain

Publications (1)

Publication Number Publication Date
ATE293458T1 true ATE293458T1 (de) 2005-05-15

Family

ID=21820954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97938475T ATE293458T1 (de) 1996-08-23 1997-08-21 Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen

Country Status (9)

Country Link
US (2) US6187338B1 (de)
EP (1) EP0942752B1 (de)
JP (1) JP2001500121A (de)
AT (1) ATE293458T1 (de)
AU (1) AU4078897A (de)
CA (1) CA2264182A1 (de)
DE (1) DE69733081T2 (de)
ES (1) ES2241055T3 (de)
WO (1) WO1998007447A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69733081T2 (de) * 1996-08-23 2006-05-11 Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
AU784225B2 (en) * 1997-09-08 2006-02-23 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
WO1999012537A1 (en) 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU2002301362B8 (en) * 1997-09-08 2006-05-04 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
PL345340A1 (en) 1998-07-09 2001-12-17 Warner Lambert Co Compositions comprising gaba analogs and caffeine
CN1221249C (zh) 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
US6309858B1 (en) 1998-09-29 2001-10-30 Syntex (U.S.A.) Llc T-type calcium channel variants; compositions thereof; and uses
ES2209843T3 (es) 1999-02-18 2004-07-01 Ortho-Mcneil Pharmaceutical, Inc. Aroil aminoacil pirroles para uso en el tratamiento del dolor neuropatico.
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU4334900A (en) * 1999-04-09 2000-11-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
WO2001000191A2 (en) * 1999-06-23 2001-01-04 Warner-Lambert Company Use of fosphenytion for the treatment of acute neuropathic pain
EP1210118B1 (de) * 1999-08-20 2004-12-08 Ortho-McNeil Pharmaceutical, Inc. Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
WO2002002521A2 (en) 2000-06-30 2002-01-10 Ortho-Mcneil Pharmaceutical, Inc. Aroyl aminoacyl pyrrole compounds and their pharmaceutical use
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
DE60143671D1 (de) 2001-06-07 2011-01-27 Sang Christine Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
CN1274306C (zh) 2001-09-03 2006-09-13 纽朗制药有限公司 包含加巴喷丁或其类似物和α－氨基酰胺的药物组合物及其止痛应用
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
KR20040096571A (ko) * 2002-02-13 2004-11-16 베쓰 이스라엘 디코니스 메디칼 센터 인크 혈관 질환을 치료하는 방법
HRP20040846A2 (en) * 2002-02-26 2005-06-30 Ortho-Mcneil Pharmaceutical Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
CN1674942A (zh) * 2002-06-21 2005-09-28 联邦高等教育系统匹兹堡大学 氧化氮、血红素加氧酶－1和血红素降解产物的药学用途
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
DK1524981T3 (da) * 2002-07-29 2009-06-22 Glaxo Group Ltd Sammensætninger med vedvarende frigivelse indeholdende lamotrigin
WO2004050081A1 (en) * 2002-12-02 2004-06-17 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
HUP0300929A3 (en) * 2003-04-09 2005-06-28 Richter Gedeon Vegyeszet Analgetic and/or muscle relaxant pharmaceutical composition
WO2005019166A2 (en) * 2003-06-11 2005-03-03 Neuromolecular, Inc. Method of targeting a therapeutic agent
US20040265364A1 (en) * 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
EP1686967A4 (de) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd Carvedilol-freie base, salze, wasserfreie formen oder solvate davon, entsprechende pharmazeutische zusammensetzungen, formulierungen mit kontrollierter freisetzung und behandlungs- oder abgabeverfahren
EP1715843A1 (de) * 2004-01-29 2006-11-02 Neuromolecular Inc. Kombination eines nmda-rezeptor-antagonisten und eines mao-hemmers oder eines gadph-hemmers zur behandlung von erkrankungen im zusammenhang mit dem zentralen nervensystem
EP1727538A2 (de) * 2004-02-13 2006-12-06 Neuromolecular Inc. Kombination aus einem nmda-rezeptor-antagonisten und einem antiepileptikum zur behandlung von epilepsie und anderen störungen des zns
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
JP4912312B2 (ja) * 2004-08-24 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗痙攣薬として有用な新規なベンゾ−縮合ヘテロアリールスルファミド誘導体
RS51411B (sr) * 2004-09-10 2011-02-28 Newron Pharmaceuticals S.P.A. Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala
AU2005309601A1 (en) 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
EP2623099A1 (de) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Zusammensetzung und Verfahren zur Behandlung neurologischer Erkrankungen
US20060286167A1 (en) * 2005-05-02 2006-12-21 Jane Staunton Compositions and methods for the treatment of neurodegenerative diseases
US20090143450A1 (en) * 2005-05-06 2009-06-04 University Of Maryland, Baltimore Method for treating central pain syndrom or for inducing centrally generated pain in an animal model
CA2609185A1 (en) 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
EP2465499A3 (de) 2005-06-27 2013-02-13 Ono Pharmaceutical Co., Ltd. Therapeutischer Wirkstoff zur Behandlung von Schmerzen
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
IN266803B (de) 2005-12-22 2015-06-03 Newron Pharm Spa
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070191452A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
AU2007337097A1 (en) * 2006-12-22 2008-07-03 Allergan, Inc. Alpha-2B adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
US20100279984A1 (en) * 2007-10-09 2010-11-04 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
WO2010008776A2 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
AU2009296457A1 (en) * 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
JP5885668B2 (ja) * 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
EA201990684A1 (ru) 2013-12-24 2020-12-30 Вирджиния Коммонвелт Юниверсити Способы применения оксигенированных холестеролсульфатов (ocs)
FI3551166T3 (fi) 2016-12-06 2024-10-04 Topical Innovations B V Topikaalinen fenytoiini perifeerisen neuropaattisen kivun hoitoon
EP3551182B1 (de) 2016-12-06 2025-03-19 Topical Innovations B.V. Topische pharmazeutische zusammensetzung mit phenytoin und einem (co -)analgetikum zur behandlung von chronischen schmerzen
JP2021521227A (ja) * 2018-04-16 2021-08-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 神経障害性疼痛を処置する方法
CN113557018A (zh) * 2018-09-14 2021-10-26 国立大学法人富山大学 急性带状疱疹疼痛的治疗剂
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
BR112022022243A2 (pt) 2020-05-01 2022-12-20 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Bloqueadores do canal de proteína e e inibidores de orf3 como agentes anti-covid-19.
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694010A (en) * 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
US4906638A (en) * 1987-12-22 1990-03-06 Nova Pharmaceutical Corporation Dextromethorphan potentiator for anticonvulsant composition and method
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
DE69733081T2 (de) * 1996-08-23 2006-05-11 Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists

Also Published As

Publication number Publication date
JP2001500121A (ja) 2001-01-09
US6406716B2 (en) 2002-06-18
DE69733081D1 (de) 2005-05-25
EP0942752A1 (de) 1999-09-22
EP0942752B1 (de) 2005-04-20
US6187338B1 (en) 2001-02-13
AU4078897A (en) 1998-03-06
CA2264182A1 (en) 1998-02-26
DE69733081T2 (de) 2006-05-11
ES2241055T3 (es) 2005-10-16
US20010008889A1 (en) 2001-07-19
WO1998007447A1 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
DE69733081D1 (de) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
ATE301994T1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
ATE214277T1 (de) Schmerzlindernde arzneistoffzusammensetzung
DE69634609D1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
HUP0004532A2 (en) Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
PL318172A1 (en) Novel analgesic pharmaceutic preparation
ATE288444T1 (de) Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
BG103552A (bg) Терапевтични средства
NO20053105D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
BR9508671A (pt) Método de alívio da dor e composição terapêutica
DK1003494T3 (da) (d)-metadon, et ikke-opioidt analgetikum
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
PL312198A1 (en) Application of procaine in obtaining a pharmaceutical preparation of analgesic activity with minimum motorial blocking effect
ATE280575T1 (de) Transdermales therapeutisches system zur anwendung von candesartan
ATE74505T1 (de) Schmerzpraeparat.
MX9707719A (es) Preparado en combinacion que contiene tramadol y un antagonista del canal de calcio.
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties